Event Brief of Vertex Pharmaceuticals Incorporated Strengthens HCV Drug Development Portfolio, Adds Novel Polymerase Inhibitors to Shape New Combinations with Telaprevir Conference Call - Final

Source :: Fair Disclosure Wire. March 3, 2009
Publication Year :: 2009
Abstract: PARTICIPANTS . Michael Partridge, Vertex Pharmaceuticals, Inc., Senior Director of Strategic Communications . Kurt Graves, Vertex Pharmaceuticals, Inc., EVP, Chief Commercial Officer, Head of Development . Freda Lewis-Hall, Vertex Pharmaceuticals, [...]

Subjects :: Vertex Pharmaceuticals Inc. -- Planning
Interferon -- Planning
Protease inhibitors -- Dosage and administration -- Planning
Medical research
Medicine, Experimental
Financial analysts -- Planning
Proteases -- Planning
Financial markets
Drug therapy, Combination
Biological response modifiers
Securities offerings
Hepatitis C -- Care and treatment
Pharmaceutical industry -- Planning
Company business planning
Business

Tools